Itacitinib
Itacitinib is a pharmaceutical drug with 46 clinical trials. Currently 8 active trials ongoing. Historical success rate of 56.3%.
Success Metrics
Based on 18 completed trials
Phase Distribution
Phase Distribution
20
Early Stage
24
Mid Stage
1
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
50.0%
18 of 36 finished
50.0%
18 ended early
8
trials recruiting
46
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Itacitinib in Advanced Hepatocellular Carcinoma
Itacitinib for the Treatment Steroid Refractory Immune Related Adverse Events Arising From Immune Checkpoint Inhibitors
Study of Itacitinib in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)
Itacitinib for the Prevention of Graft Versus Host Disease
Clinical Trials (46)
Itacitinib in Advanced Hepatocellular Carcinoma
Itacitinib for the Treatment Steroid Refractory Immune Related Adverse Events Arising From Immune Checkpoint Inhibitors
Study of Itacitinib in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)
Itacitinib for the Prevention of Graft Versus Host Disease
Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy
An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer
Treatment of Non Severe Hemophagocytosis Lymphohistiocytosis With ITACITINIB
A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib
Safety and Efficacy of Itacitinib in Adults With Systemic Sclerosis
Itacitinib for the Treatment of Bronchiolitis Obliterans Syndrome After Donor Hematopoietic Cell Transplant
Safety and Efficacy of Itacitinib in Combination With Corticosteroids for Treatment of Graft-Versus-Host Disease in Pediatric Subjects
GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease
Safety and Efficacy of Itacitinib in Participants With Bronchiolitis Obliterans Syndrome Following Lung Transplantation
GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients
GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease
To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)
Expanded Access Use of Itacitinib to Treat a Single Patient With STAT1 Gain of Function (GOF) Disease
Itacitinib + Everolimus in Hodgkin Lymphoma
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 46